Humacyte reports Q4 results, FDA priority review for HAV By Investing.com
© Reuters.
Humacyte, Inc. (HUMA), a biotechnology company specializing in regenerative medical technologies, has reported its financial results for the fourth quarter of 2023. During the earnings call, the company highlighted the…
